))
Are CROs Losing Relevance in the Age of DCTs?
Manage episode 446551801 series 3506216
Innehåll tillhandahållet av Darshan Kulkarni. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Darshan Kulkarni eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
In this episode, Isaac Rodriguez- Chavez and I discuss the impact of DCTs on sponsor relationships, CROs, and industry dynamics with the FDA.
We discuss,
1. How will DCTs impact sponsor relationships with CROs?
2. How do small CROs and sponsors adapt to emerging trends?
3. How do new trends impact industry relationships with the FDA?
4. Does DCT allows the FDA to advise sponsors?
5. What is the role of technology in DCTs?
6. How do DCTs reduce the cost of bringing drugs to the market?
7. What are the risks and advantages of DCTs?
8. What are the initial risks of DCTs?
9. Does the FDA even have jurisdiction over patient privacy?
137 episoder
Dela
